The expression levels of mPD-L1 on tumor cells tend to be associated, to some extent, with cancer progression and are predictive biomarkers of tumorigenesis, unfavorable outcomes, and improved response to treatment with PD-1/PD-L1 blockades in gastric [42], breast [43], renal [44], and ovarian cancers [35]. The gene discussed is CD274; the disease is neoplasm.